Description

Simple

A medication used to improve the quality of images with an MRI (magnetic resonance imaging) scan, a test that helps to see various parts of the body and find problems.

Clinical

A medication used to improve the contrast of MRI scans for better visualization.

Overview

Gadoteridol provides contrast enhancement of the brain, spine and surrounding tissues resulting in improved visualization (compared with unenhanced MRI) of lesions with abnormal vascularity or those thought to cause a disruption of the normal blood brain barrier. Gadoteridol can also be used for whole body contrast enhanced MRI including the head, neck, liver, breast, musculoskeletal system and soft tissue pathologies. n MRI, visualization of normal and pathological brain tissue depends in part on variations in the radiofrequency signal intensity that occur with changes in proton density, alteration of the T1, and variation in T2. When placed in a magnetic field, gadoteridol shortens the T1 relaxation time in tissues where it accumulates. Abnormal vascularity or disruption of the blood-brain barrier allows accumulation of gadoteridol in lesions such as neoplasms, abscesses, and subacute infarcts.

Pharmacology

Indication

Gadoteridol is an MRI contrast agent used for contrast enhancement of the brain, spine and surrounding tissues resulting in improved visualization (compared with unenhanced MRI) of lesions with abnormal vascularity or those thought to cause a disruption of the normal blood brain barrier. Gadoteridol... Read more

Pharmacodynamic

Information currently not available.

Mechanism of action

Based on the behavior of protons when placed in a strong magnetic field, which is interpreted and transformed into images by magnetic resonance (MR) instruments. Paramagnetic agents have unpaired electrons that generate a magnetic field about 700 times larger than the proton's field, thus disturbing... Read more

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

204 ± 58 mL/kg

Clearance

1.50+/- 0.35 mL/ min/kgrenal cl=1.41 +/- 0.33 mL/ min/kg

Half life

Distribution 12 minutes (mean), elimination 100 minutes (mean).

Route of elimination

Gadoteridol is eliminated in the urine with 94.4 ± 4.8% (mean ± SD) of the dose excreted within 24 hours post-injection.

Toxicity

Information currently not available.

Adverse Effects

Effect Regions Age Groups Incidences Evidence Type
Headache US
  • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Chest Pain US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Fever US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Pain at injection site US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Injection site reaction US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Facial edema US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Pain US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Neck rigidity US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Nausea US
    • adult
  • Kind: experimental
    • Percent: 1%
  • Clinical Trial
    Taste perversion US
    • adult
  • Kind: experimental
    • Percent: 1%
  • Clinical Trial
    Prolonged P-R Interval US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Hypotension US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Elevated Heart Rate US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Flushed Feeling US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Vasovagal reaction US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Anaphylactoid reactions US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Tingling Sensation in Throat US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Laryngismus US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Itching US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Watery eyes US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Abdominal Cramps US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Anxiety US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Vomiting US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Loose Bowel US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Paresthesia US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Dizziness US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Edematous tongue US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    A-V Nodal Rhythm US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Dry Mouth US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Gingivitis US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Itching tongue US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Cough US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Rhinitis US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Rash Macular Papular US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Pruritus US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Rash US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Staring Episode US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Mental Status Decline US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Loss of Coordination in Arm US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Syncope US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Dyspnea US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Seizure US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Urticaria US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Tingling Sensation of Extremity and Digits US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Hives US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Tinnitus US
    • adult
  • Kind: experimental
    • Percent: <1%
  • Clinical Trial
    Cardiac Arrest US
    • adult
    Clinical Trial
    Malaise US
    • adult
    Clinical Trial
    Hypertension US
    • adult
    Clinical Trial
    Bradycardia US
    • adult
    Clinical Trial

    Contraindications

    Information currently not available.

    Food Interactions

    Information currently not available.